Randomized Withdrawal Study in Patients With Schizophrenia
Trial details
- Registry ID
- NCT06961968
- Phase
- Phase 3
The FDA approved iloperidone (Fanapt) on 6 May 2009.
Drug identity checked against registry records
Also recorded as Fanapt
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Randomized Withdrawal Study in Patients With SchizophreniaNCT06961968 | Vanda Pharmaceuticals | Phase 3 | Recruiting | 2027-11Estimated |
| Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionNCT07090161 | Vanda Pharmaceuticals | Phase 2 | Recruiting | 2026-10Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2009-05-06Day | iloperidone | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA022192", "applicant_as_listed_by_fda": "VANDA PHARMS INC", "brand_names": ["FANAPT"], "active_ingredients": ["ILOPERIDONE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20090506", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |